2003
Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy
Schreibman T, Friedland G. Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. Clinical Infectious Diseases 2003, 38: 257-262. PMID: 14699459, DOI: 10.1086/380792.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countCD4 cell countAntiretroviral therapyCell countLymphocyte countHuman immunodeficiency virus (HIV) diseaseOpportunistic infection prophylaxisPotential surrogate markerResource-limited settingsHIV diseaseInfection prophylaxisLaboratory markersOpportunistic infectionsSurrogate markerDisease progressionClinical utilityImmune functionTherapeutic interventionsTherapyKey laboratory measurementsMonitoring responseVirus diseaseLack of availabilityDiseaseCount
1994
Laboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts